Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11

Showing 11 citing articles:

Novel clinical trial designs emerging from the molecular reclassification of cancer
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 2
Longer survival with precision medicine in late-stage cancer patients
Christophe K. Mapendano, Anne Krogh Nøhr, Mads Sønderkær, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104089-104089
Open Access
Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation
Ioannis Zerdes, Panagiotis Filis, Georgios Fountoukidis, et al.
JNCI Journal of the National Cancer Institute (2025)
Closed Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
George W. Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Nectin-4 Expression Patterns and Therapeutics in Oncology
Mina Nikanjam, Judith Pérez-Granado, Mark W. Gramling, et al.
Cancer Letters (2025), pp. 217681-217681
Closed Access
The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery
Jihyeob Mun, Byungho Lim
Drug Discovery Today (2024) Vol. 29, Iss. 12, pp. 104203-104203
Open Access | Times Cited: 1
Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors
Vladimir Lazar, Éric Raymond, Shai Magidi, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
Jacopo Azzollini, Iolanda Capone, Matteo Duca, et al.
Tumori Journal (2024)
Closed Access
Dissecting the roles of prosaposin as an emerging therapeutic target for tumors and its underlying mechanisms
Lirong Yan, Zhenpeng Wen, Yi Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117551-117551
Closed Access
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide
Jacob J. Adashek, Javier Muñoz, Razelle Kurzrock
Med (2024)
Open Access
Deep multi-omics integration approach reveals new molecular features of uterine leiomyosarcoma
Raul Maia Falcão, Jorge Estefano Santana de Souza, Jordi Gonzalez‐Molina, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024), pp. 167632-167632
Open Access
Page 1

Scroll to top